Purobien Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 14.43%
(FY 2023)
- Profit 23.22%
(FY 2023)
- Ebitda -51.00%
(FY 2023)
- Net Worth 16.64%
(FY 2023)
- Total Assets 18.98%
(FY 2023)
About Purobien Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Vijay Aggarwal and Pranshul Aggarwal serve as directors at the Company.
- CIN/LLPIN
U24290DL2019PTC355703
- Company No.
355703
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Purobien Lifesciences Private Limited offer?
Purobien Lifesciences Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Fitness Supplements, Whey Protein, Weight Gain Nutrition.
Who are the key members and board of directors at Purobien Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijay Aggarwal  | Director | 30-Sep-2019 | Current |
| Pranshul Aggarwal | Director | 17-Mar-2021 | Current |
Financial Performance of Purobien Lifesciences.
Purobien Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 14.43% increase. The company also saw a substantial improvement in profitability, with a 23.22% increase in profit. The company's net worth Soared by an impressive increase of 16.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Purobien Lifesciences?
In 2023, Purobien Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Purobien Nutrition Private LimitedActive 4 years 10 monthsVijay Aggarwal and Pranshul Aggarwal are mutual person
Associated Formulations Private LimitedActive 6 years 10 monthsPranshul Aggarwal is a mutual person
Vitascientica Private LimitedActive 5 years 5 monthsVijay Aggarwal and Pranshul Aggarwal are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Purobien Lifesciences?
Purobien Lifesciences has a workforce of 10 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Purobien Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Purobien Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
